At a Glance
- Company: Matica Biotechnology (CHA Biotech subsidiary)
- Location: US-based CDMO
- Deal value: Confidential
- Focus area: Adenovirus-based cell/gene therapy
- Next steps: Cell-line establishment, process development, QC services
What happened?
CHA Biotech’s US-based CDMO arm, Matica Biotechnology, has secured a new contract to support development of an adenovirus-based cell and gene therapy. The agreement covers cell-line establishment, process development, and quality control services for the client programme.
Why does it matter?
Adenovirus vectors are widely used in cell and gene therapies for their high transduction efficiency and large payload capacity, but manufacturing remains complex and capacity-constrained. This deal validates Matica’s capabilities in viral vector CDMO services at a time of surging demand for outsourced AAV, lentiviral and adenoviral production.
Who’s behind it?
Matica Biotechnology, a CHA Biotech subsidiary, provides end-to-end CDMO services for biologics and advanced therapies with a focus on mammalian cell culture and viral vectors. CHA Biotech, the Korean parent, leverages Matica’s US infrastructure to serve global clients needing GMP-compliant process development and scale-up.
How was it achieved?
The contract encompasses core CGT workflow elements: custom cell-line generation optimised for adenovirus production, upstream/downstream process development, and comprehensive QC including potency assays, sterility and vector integrity testing. Matica’s platform supports rapid tech transfer and clinical-scale manufacturing.
What’s next?
Matica will execute the contracted milestones, potentially advancing the adenovirus programme toward IND-enabling studies and clinical trials. The engagement reinforces Matica’s position in the competitive CGT CDMO market and could lead to follow-on commercial manufacturing or platform licensing opportunities.